(Q37935034)

25 August 2017

1 reference

title

Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia (English)

1 reference

25 August 2017

0 references

0 references

0 references

Stefan Verlohren

1

0 references

Ralf Dechend

series ordinal

3

object named as

Ralf Dechend

1 reference

25 August 2017

Holger Stepan

2

1 reference

25 August 2017

language of work or name

English

0 references

publication date

1 January 2012

1 reference

25 August 2017

1 reference

25 August 2017

volume

122

1 reference

25 August 2017

issue

2

1 reference

25 August 2017

page(s)

43-52

1 reference

Pathogenesis and genetics of pre-eclampsia

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Prediction of adverse outcomes by common definitions of hypertension in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Vascular endothelial growth factor is increased in patients with preeclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Soluble endoglin contributes to the pathogenesis of preeclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Circulating angiogenic factors and the risk of preeclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

The fetal vascularisation of term human placental villi. II. Intermediate and terminal villi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Regulation of human placental development by oxygen tension

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Oxygen regulates human cytotrophoblast differentiation and invasion: implications for endovascular invasion in normal pregnancy and in pre-eclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3)

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

The effects of angiogenic growth factors on extravillous trophoblast invasion and motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Vascular endothelial growth factor is a chemoattractant for trophoblast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

A recently evolved novel trophoblast-enriched secreted form of fms-like tyrosine kinase-1 variant is up-regulated in hypoxia and preeclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

The discovery of the placental growth factor and its role in angiogenesis: a historical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Changes in endovascular trophoblast invasion and spiral artery remodelling at term in a transgenic preeclamptic rat model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Inhibition of Trophoblast-Induced Spiral Artery Remodeling Reduces Placental Perfusion in Rat Pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Failure to up-regulate VEGF165b in maternal plasma is a first trimester predictive marker for pre-eclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Dysregulation of the Circulating and Tissue-Based Renin-Angiotensin System in Preeclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

A study of angiotensin II pressor response throughout primigravid pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Uterine vascular function in a transgenic preeclampsia rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Preeclampsia: an endothelial cell disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Maternal plasma vascular endothelial growth factor concentrations in normal and hypertensive pregnancies and their relationship to peripheral vascular resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Vascular endothelial growth factor and placenta growth factor in intrauterine growth-restricted fetuses and neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Soluble fms-Like Tyrosine Kinase 1 Is Increased in Preeclampsia But Not in Normotensive Pregnancies with Small-for-Gestational-Age Neonates: Relationship to Circulating Placental Growth Factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Twin-to-twin transfusion syndrome: an antiangiogenic state?

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Circulating angiogenic factors and placental abruption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Unexplained fetal death: another anti-angiogenic state.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Prediction of pre-eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy-associated plasma protein-A, free beta-human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks' gestation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Second-trimester uterine artery Doppler screening in unselected populations: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Angiogenic growth factor levels in maternal and fetal blood: correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

First Trimester Placental Growth Factor and Soluble Fms-Like Tyrosine Kinase 1 and Risk for Preeclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Fetal sex determination using circulating cell-free fetal DNA (ccffDNA) at 11 to 13 weeks of gestation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia--a step forward but not the definitive answer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Antioxidants for preventing pre-eclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Association between level of delivery hospital and neonatal outcomes among South Carolina Medicaid recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Perinatal regionalization and neonatal mortality in North Carolina, 1968-1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

ACOG committee opinion. Antenatal corticosteroid therapy for fetal maturation. American College of Obstetricians and Gynecologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Primary, secondary, and tertiary prevention of pre-eclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Financial impact of a novel pre-eclampsia diagnostic test versus standard practice: a decision-analytic modeling analysis from a UK healthcare payer perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

A role of the anti-angiogenic factor sVEGFR-1 in the ‘mirror syndrome’ (Ballantyne's syndrome)

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20110097

21 January 2018

Identifiers

DOI

10.1042/CS20110097

1 reference

25 August 2017

1 reference